Consensus estimates place Q2 revenue at $280.45 million and FFO per share at $0.90, with the stock currently trading at $39.24 against a mean analyst target of $45.10. The primary metric investors are watching is the total portfolio occupancy rate, which serves as a critical barometer for West Coast office demand recovery.
Recent performance has been pressured by persistent vacancies in the San Francisco tech corridor and higher interest expenses impacting the bottom line. However, analysts are looking for potential upside from the company’s life science development deliveries and any stabilization in leasing spreads.